Ethical Dilemmas in Pharmacogenomics: Balancing Innovation with Privacy and Equity
Ethical Dilemmas in Pharmacogenomics: Balancing Innovation with Privacy and Equity
-
-
FOR IMMEDIATE RELEASE – American Pharmacogenomics Association Issues Statement on Final FDA Rule for Laboratory Developed Tests (LDTs)
The American Pharmacogenomics Association (APGxA) today issued a statement on the Food and Drug Administration’s (FDA) final rule regarding the regulation of laboratory-developed tests (LDTs).
-
FDA Drops Final Rule On LDTs
Explore the impact of the FDA’s Ruling for LDTs on pharmacogenomics to understand the future of personalized medicine and testing compliance.
-
Is an FDA Crackdown with 510(k) Clearances for LDTs Inevitable?
Explore the possible intensification of FDA regulations concerning 510(k) clearances for LDTs in the evolving landscape of laboratory testing.
